The efficacy of oral treatment with chewable tablets containing afoxolaner 2.27% w/w (NexGard ® , Merial, now part of Boehringer-Ingelheim) or 1.875% w/w of afoxolaner and 0.375% w/w milbemycin oxime (NexGard Spectra ® , Merial, now part of Boehringer-Ingelheim) was each assessed in eight dogs diagnosed with generalized demodicosis in this parallel group designed, blinded, randomized, single center negative controlled, efficacy study. Afoxolaner at the therapeutic dose (as close as possible to 2.5 mg/kg) was administered to Group 2 dogs, and afoxolaner (as close as possible to 2.5 mg/kg) with milbemycin oxime at 0.5 mg/kg was administered to Group 3 dogs on Days 0, 28 and 56. All dogs were observed once daily for general health starting on Day −7 until Day 84. All dogs were clinically examined on Days −7, −2, 14, 28, 42, 56, 70 and 84. Dogs were weighed on Days −7, −2, 27, 55, and 84. Live mite counts (based on five scrapings per dog and occasion) and clinical assessments, including photographic documentation, were performed on Days −2, 28, 56 and 84. Three monthly treatments with NexGard or NexGard Spectra against generalized demodicosis in dogs were highly effective resulting in a 99.9% and 100% efficacy against mites, respectively. After treatment with NexGard, only three live mites were recovered in five scrapings in one dog on Day 84. After treatment with NexGard Spectra, no mites were recovered in any scraping on any dogs in this group by Day 84. Both treatments resulted in a marked reduction of skin lesions and >90% hair-regrowth at three months after the initial treatment. Reduction of live mite counts was
Introduction
Demodectic mites (Demodex canis Leydig, 1859) are considered normal fauna of the dog's skin, typically acquired by neonates, from the dam, via skin contact in the first days of life [1] [2] [3] . In individual animals, the mites can proliferate, potentially causing the dog to manifest the parasitic skin disease, canine demodicosis.
Canine demodicosis is classically divided into two clinical presentations, localized and generalized demodicosis. The localized form appears as patchy alopecia on the muzzle or limbs, occasionally with mild erythema in younger dogs, and most cases resolve with time [4] . However, generalized demodicosis results in moderate to severe disease and can even be fatal without appropriate treatment. Generalized demodicosis can occur in both young and old dogs, especially those experiencing immunosuppression, due to systemic disease, parasitism, chemotherapy, malnutrition, or other causes [2] [4] [5] .
Historically, generalized demodicosis was a difficult disease to treat effectively, but the isoxazolines have made localized and generalized demodicosis much easier to control. Even though demodicosis is easier to control, the practitioner still must consider the individual cause of generalized demodicosis, especially in young adult dogs. When generalized demodicosis is diagnosed in a young adult dog, international treatment guidance is that the dog should be spayed or neutered [3] [5] .
Afoxolaner is an isoxazoline administered monthly to protect dogs against fleas and ticks [NexGard ® (afoxolaner) and NexGard Spectra ® (afoxolaner/milbemycin oxime)] [6] [7] [8] . It is administered at the minimum therapeutic dose of 2.5 mg/kg. Afoxolaner efficacy against D. canis involving dogs diagnosed with generalized demodicosis has been recently demonstrated in a well-controlled laboratory study where dosing occurred on Days 0, 14, 28 and 56 [9] . In the well-controlled study described in this paper, dogs with generalized demodicosis were only treated monthly, on Days 0, 28 and 56.
Materials and Methods

Study design and treatment
The design and conditions of this study were approved by the local Animal [5] . The dogs were leased from various owners who signed an owner consent form for the inclusion of their dogs in the study. The dogs were returned to their household after completing the study. They originated from Bloemfontein (South Africa) and its suburbs, and were privately owned.
The study followed a randomized block design. The 24 infected dogs included underwent a 7 day acclimation period. On Day −1, dogs confirmed positive by skin scrapings on Day −2 were included. Dogs were randomly allocated to three groups using total (immature plus adult) live mite counts as ranking criteria. (Table 2 ). All dogs included in the study were of mixed breeds and at least 6 months of age, with gender and weight on inclusion described (Table 3 ).
The dogs in Groups 2 and 3 were treated with their respective investigational products on Days 0, 28 and 56. The dogs were observed hourly for four hours after IVP administration to the last animal, for possible adverse events (AEs). covered the kennels and the dogs were therefore not exposed to rain. The animals were exposed to ambient temperatures and lighting was provided by natural Table 3 . Animal details and body weights on inclusion (All dogs were >6 months of age). 
Clinical symptom evaluation
The clinical symptoms and the extent of demodectic lesions on each dog were assessed on the same days during which scrapings were made and recorded. The following parameters were assessed for each dog and sketched on a silhouette (left-and right-hand side) of a dog:
• body areas covered by casts, scales and crusts;
• body areas with hair loss (1 = slight thinning of hair; 2 = conspicuous hair loss; 3 = no hair); • body areas with erythema;
• estimated hair re-growth (Table 4) . Table 4 . Semi-quantitative assessment parameters used to score hair re-growth [9] . 
Statistical analysis
The primary assessment variable in this study was the efficacy of the investigational products (IVPs) at the minimum therapeutic dose of 2.5 mg/kg afoxolaner against mites as compared to controls at each time-point. Due to the fact that small and even zero live mite counts could be recorded, it could be expected that the mite counts would not follow a normal distribution. It was therefore decided that efficacy calculations would be based on geometric means rather than arithmetic means. Before the formal analyses were performed, data were log-transformed (x = log(x + 1)). Percentage efficacy for the IVP groups against mites was calculated as follows: To confirm the acaricidal efficacy results, mite counts were formally analyzed using a Linear Mixed Model. Treatment group was a fixed factor in the model, while the block to which each dog was assigned for randomization was included as a random effect. The IVP groups were compared against the control group using a two-sided F-test with the level of significance set to α = 0.05. 3) The number of mites at each assessment day and for each group was tabulated with the following descriptive statistics: mean, median, standard deviation (SD), geometric mean, minimum and maximum.
The IVP groups were only compared with the control group and not with each other.
The pre-administration and post-administration mite counts were compared by ANOVA with administration (pre or post) and animal effects on mite count data. The level of significance of the formal tests was set at 5%, all tests were two-sided. SAS Version 9.3 TS Level 1M2 was used for all the statistical analyses.
Clinical signs and symptoms
Data recorded during clinical assessments on casts, scales, crusts and area(s)
of hair loss and erythema were summarized for each dog. Overall changes in clinical appearance were also reported by pre-and post-administration photographs taken from each dog. These results showed the overall extent and resolution of lesions for each dog.
As a secondary criterion, the number of dogs affected by erythema, casts, scales and crusts was compared between the pre-administration and different post-administration assessment days. A semi-quantitative assessment of hair re-growth was also conducted and a score awarded to each dog on the different post-administration assessment days (Table 3) . Photographic documentation was used to highlight changes in skin condition (Figures 1-3 ).
Results
Antiparasitic efficacy
Efficacy against D. canis, using geometric means, is summarized in Table 5 .
All the dogs were positive for the presence of mites prior to the first treatment.
For both treated groups on all post-treatment assessment days, the mite counts were statistically significantly reduced (p < 0.05) compared to the counts at initiation (Day −2) ( 
% decrease in mite counts
The number of live D. canis mites based on skin scrapings (individual) and corresponding percentage reductions for each assessment day is summarized in Tables 6-8 and percentage decrease per group in Table 9 .
The arithmetic mean mite counts recorded in the negative control group decreased from baseline (Day −2) to 48.8% on Day 28, 12.0% on Day 56 and 11.6% N: Actual mite counts; Decrease = Pre-administration mite count − Post-administration mite count; % Decrease = ((Pre-administration mite count − Post-administration mite count)/Pre-administration mite count) * 100; Group 2: Dogs were treated orally with the IVP NexGard ® . N: Actual mite counts; Decrease = Pre-administration mite count − Post-administration mite count; % Decrease = ((Pre-administration mite count − Post-administration mite count)/Pre-administration mite count) * 100; Group 3: Dogs were treated orally with the IVP NexGard Spectra ® . Open Journal of Veterinary Medicine 
Clinical efficacy
During the assessments of clinical signs and symptoms related to demodicosis, the following were concluded: in Group 1 (negative control), the occurrence of crusts remained rather similar and occurrence of both casts and scales increased by Day 84. In Group 2 (NexGard), the occurrence of crusts decreased and no casts and scales were present by Day 84. In Group 3 (NexGard Spectra), no crusts and scales were present by Day 84. Erythematous papules were never observed for any of the groups. The occurrence of crusts, casts and scales at pre-treatment evaluations as well as the resolution thereof during the post-treatment assessment period, are summarized in Table 10 for the three groups.
Hair re-growth, where the percentage of hair re-growth was compared to the recorded hair growth prior to IVP treatment, is summarized in Table 11 .
Since resolution of clinical signs, including alopecia, is the desired clinical outcome, analyses >90% v. <90% were statistically compared for the groups.
Fisher's Exact Test for Count Data; Alternative: 2-sided. [10] was used for these analyses, as it allows comparison with groups at 0, which is not possible with . These results are shown in Table 12 .
All IVP treated dogs showed > 90% hair regrowth on Day 84, which can be seen in the photographic documentation (Figures 1-3 ).
Health observations
Due progressive health deterioration associated with demodicosis, of one of the dogs in the negative control group, had to be humanely euthanized. The Open Journal of Veterinary Medicine treatment of the dogs with Nexgard ® and Nexgard Spectra ® (respectively) were however well accepted and no investigational product-related health abnormalities were observed throughout the study. 
Discussion and Conclusion
An initial clinical assessment of afoxolaner activity against demodectic mange was done with bi-weekly treatments with NexGard at Days 0, 14 and then 28, a strategy based, in-part, on rapidly achieving a steady state of afoxolaner in the blood of the study animals [6] . This was considered to be safe because this schedule was performed in the NexGard and NexGard Spectra target animal safety studies conducted for its registration in the USA and Europe [7] [8] . In those studies, no adverse events related to the treatment were observed during the time that three doses were administered biweekly. The bi-weekly protocol was highly effective, but necessity of the shortened dosing interval for treatment of demodicosis was questioned by the authors [9] . Nearly simultaneously, field reports of high efficacy with regular (monthly) dosing demonstrated that the higher systemic drug levels afforded by bi-weekly dosing may not be necessary to clear demodectic mites [11] .
This well-controlled study was initiated, and it validated the field reports of Chavez and others [12] demonstrating outstanding efficacy was provided by regular monthly dosing of afoxolaner against demodectic mange. In this study, NexGard or NexGard Spectra, the 50 dogs experienced a >97.5% reduction in live mite counts [13] .
In conclusion, three monthly treatments with NexGard or NexGard Spectra against generalized demodicosis in dogs were highly effective resulting in a 99.9% and 100% efficacy against mites, respectively. Both treatments resulted in a marked reduction of skin lesions and >90% hair-regrowth at three months after the initial treatment.
